Francis D. Moore Professor of Surgery, Brigham and Women's Hospital
Gastroenterology
Dr. Francis D. Moore, MD
|
|
Give Review
Dr. Francis D. Moore is an expert in the field of Gastroenterology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He has 3 awards "Meaningful Use Stage 1 Certification", "Super Doctor" and "Fellow (FACS)". Francis Moore is a published physician. He has 61 papers published. The most current publication "Bethesda Categorization of Thyroid Nodule Cytology & Prediction of Thyroid Cancer Type and Prognosis." Dr. Francis D. Moore accepts Medicare payments and is listed with Medicare.gov.
Publications
- Bethesda Categorization of Thyroid Nodule Cytology & Prediction of Thyroid Cancer Type and Prognosis.
- False negative cytology in large Thyroid nodules.
- Primary Hyperparathyroidism After Roux-en-Y Gastric Bypass.
- Surgeons and Patients Disagreeon the Potential Consequences from HypoParathyroidism.
- Recalcitrant hypocalcemia after Thyroidectomy in patients with previous Roux-en-Y gastric bypass.
- A standardized assessment of thyroid nodules in children confirms higher Cancer prevalence than in adults.
- Bilateral Neck Exploration Decreases Operative Time Compared to Minimally Invasive Parathyroidectomy in Patients with Discordant Imaging.
- Thyroid nodule size and prediction of Cancer.
- Hemorrhagic shock as the initial manifestation of pheochromocytoma: report of a sequential management strategy.
- Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive Cancers.
- Thyroid-specific knockout of the Tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-...
- Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical Cancers.
- Preoperative basal calcitonin and Tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thy...
- Critical role of identification of the second gland during unilateral Parathyroid surgery: a prospective review of 119 patients with concordant localization.
- Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid Cancer.
- The predictive value of the fine-needle aspiration diagnosis "suspicious for a follicular neoplasm, hurthle cell type" in patients with hashimoto Thyroiditis.
- The inflammatory response after an epidermal burn depends on the activities of mouse mast cell proteases 4 and 5.
- Accuracy of 4-dimensional computed tomography in poorly localized patients with primary Hyperparathyroidism.
- Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid Cancer.
- Inhibition of rat gut reperfusion injury with an agent developed for the mouse. Evidence that amplification of injury by innate immunity is conserved between two anima...
- Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid Cancer cells with the BRAFV600E mutation.
- Career satisfaction of women in surgery: perceptions, factors, and strategies.
- Autophagy: a new target for advanced papillary thyroid Cancer therapy.
- Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid Cancer.
- Attenuation of the effects of rat hemorrhagic shock with a reperfusion injury-inhibiting agent specific to mice.
- Restoration of skeletal muscle ischemia-reperfusion injury in humanized immunodeficient mice.
- Improved survival of murine island skin flaps by prevention of reperfusion injury.
- Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid Cancer cells.
- Surgery for Hyperparathyroidism in image-negative patients.
- Long-term assessment of a multidisciplinary approach to Thyroid nodule diagnostic evaluation.
- Decay-accelerating factor attenuates remote ischemia-reperfusion-initiated organ damage.
- Predicting future staffing needs at teaching hospitals: use of an analytical program with multiple variables.
- Innate response to self-antigen significantly exacerbates burn wound depth.
- Inherited aspects of papillary Thyroid carcinoma.
- The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion.
- Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury.
- Prevalence and distribution of carcinoma in patients with solitary and multiple Thyroid nodules on sonography.
- Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia.
- Reassessment of parathyroid hormone monitoring during parathyroidectomy for primary Hyperparathyroidism after 2 preoperative localization studies.
- Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients.
- Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM.
- Identification of the target self-antigens in reperfusion injury.
- Prophylactic Thyroidectomy in MEN-2A--a stitch in time?
- Laryngeal nerve monitoring during Thyroid surgery in pregnancy.
- Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle.
- Blunt trauma to the Thyroid: a case report.
- Validation of a method to replace frozen section during Parathyroid exploration by using the rapid Parathyroid hormone assay on Parathyroid aspirates.
- IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia-reperfusion.
- Reperfusion injury to skeletal muscle affects primarily type II muscle fibers.
- Murine hindlimb reperfusion injury can be initiated by a self-reactive monoclonal IgM.
- Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury.
- Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoParathyroidism.
- Surgical treatment of small bowel Cancer: a 20-year single institution experience.
- Decreased expression of caveolin-1 and altered regulation of mitogen-activated protein kinase in cultured bovine Parathyroid cells and human Parathyroid adenomas.
- m-CalPain colocalizes with the calcium-sensing receptor (CaR) in caveolae in parathyroid cells and participates in degradation of the CaR.
- A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor.
- Functional activity of natural antibody is altered in Cr2-deficient mice.
- Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis?
- The use of readily available equipment in a simple method for intraoperative monitoring of recurrent laryngeal nerve function during Thyroid surgery: initial experienc...
- Bronchogenic cyst masquerading as an adrenal Tumor: a case of mistaken identity.
Schools
Harvard Medical School
Brigham Womens Hosps
Harvard Med School
Procedures Preformed
- Lymph Node Biopsy or Excision
- Open Thymectomy
- ParaThyroidectomy
- Thyroid Lobectomy
- View All
Conditions Treated
- Abdominal Pain
- Crohn's Disease (Regional Enteritis)
- Diaphragmatic and-or Hiatal Hernia
- HyperparaThyroidism
- View All
Doctors Specialties
- General Surgery
- Gastroenterology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Super Doctor
- Fellow (FACS)
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Dana-Farber Cancer Institute -
Brigham and Women's Faulkner Hospital -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1073595419 | |
| NPPES Provider LastName | MOORE | |
| NPPES Provider FirstName | FRANCIS | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | General Surgery | |
| Total Claim Count | 78.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073595419 |
| Last Name Of The Provider | MOORE |
| First Name Of The Provider | FRANCIS |
| View All |
Similar Doctors
|
|
Dr. Richard M. Rothstein, MD |
|
|
Dr. Sreedhar Subramanian, MD |
|
|
Dr. Eliza J. Lee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina R. Bess, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce M. Pastor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikolaus Jilg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan D. Callow, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Thomas A. O'Gorman |